Whether PI3K-stimulating hypoglycemic agents (such as insulin, sulfonylureas, DPP4-inhibitors/GLP-1 agonist, or meglitinides) can be used without risk of tumor growth is another area in need of more research. This evidence concerns the gene INS and neoplasm.